Literature DB >> 2056323

The motor response to sequential apomorphine in parkinsonian fluctuations.

A J Hughes1, A J Lees, G M Stern.   

Abstract

Fifteen patients with Parkinson's disease and levodopa-induced motor fluctuations, were studied with repeated injections of apomorphine using two protocols to explore possible changes in the duration of motor response. One involved different interdose intervals; in the other, doses were given when the motor effects induced by the previous dose had just worn off. No significant change in the duration of motor response to sequential subcutaneous apomorphine with either protocol was found. The results suggest that rapid changes in receptor sensitivity during repeated intermittent dopaminergic stimulation do not contribute to the pathogenesis of Parkinsonian motor fluctuations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2056323      PMCID: PMC488493          DOI: 10.1136/jnnp.54.4.358

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  8 in total

1.  Motor response following repeated apomorphine administration is reduced in Parkinson's disease.

Authors:  F Grandas; J A Obeso
Journal:  Clin Neuropharmacol       Date:  1989-02       Impact factor: 1.592

2.  Diurnal responsiveness to apomorphine.

Authors:  S T Gancher; J G Nutt
Journal:  Neurology       Date:  1987-07       Impact factor: 9.910

3.  Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.

Authors:  P A Kempster; J P Frankel; M Bovingdon; R Webster; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

4.  Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.

Authors:  J Vaamonde; M R Luquin; J A Obeso
Journal:  Clin Neuropharmacol       Date:  1989-08       Impact factor: 1.592

5.  "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

Authors:  C D Marsden; J D Parkes
Journal:  Lancet       Date:  1976-02-07       Impact factor: 79.321

6.  Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval.

Authors:  R Castro; P Abreu; C H Calzadilla; M Rodriguez
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

7.  Peripheral pharmacokinetics of apomorphine in humans.

Authors:  S T Gancher; W R Woodward; B Boucher; J G Nutt
Journal:  Ann Neurol       Date:  1989-08       Impact factor: 10.422

8.  The impact of treatment with levodopa on Parkinson's disease.

Authors:  K M Shaw; A J Lees; G M Stern
Journal:  Q J Med       Date:  1980
  8 in total
  7 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine.

Authors:  M Merello; Z Pirtosek; S Bishop; A J Lees
Journal:  Clin Auton Res       Date:  1992-08       Impact factor: 4.435

Review 3.  Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.

Authors:  C Neef; T van Laar
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 4.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  A study of tolerance to apomorphine.

Authors:  J L Montastruc; M E Llau; J M Senard; M A Tran; O Rascol; P Montastruc
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 6.  Treatment of Parkinson's disease.

Authors:  M J Aminoff
Journal:  West J Med       Date:  1994-09

Review 7.  Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.

Authors:  Federico Carbone; Atbin Djamshidian; Klaus Seppi; Werner Poewe
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.